New inhaled drug for lung disease tested in healthy people first
NCT ID NCT07528703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new inhaled drug called RC010 in 42 healthy adults in China. The main goal is to check if it is safe and how the body processes it. This drug is being developed for a serious lung condition called idiopathic pulmonary fibrosis (IPF), but this study does not involve people with the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New hope for lung scarring: HSK44459 enters final trial phase
- Healthy volunteers to test experimental lung disease drug
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients
- New drug MN-001 tested for scarred lungs in tiny trial